Nemera.

CUPIDO project

Cupido aims to hit the core of cardiovascular disease, developing inhalable nanoparticles that can deliver a therapy directly to the diseased heart.

The EU-based consortium, composed of 6 academic research groups, 5 SMEs, 2 industries, and 1 pharmaceutical company, gathered a vast array of expertise and joins cutting-edge research with pre-clinical experience and industrial manufacturing.

The role of Nemera in this consortium was to develop the inhaler that administers the nanoparticles to the diseased heart.